Array BioPharma Inc. - Product Pipeline Review - H2 2011

Array BioPharma Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Array BioPharma Inc. - Product Pipeline Review - H2 2011” provides data on the Array BioPharma Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Array BioPharma Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Array BioPharma Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Array BioPharma Inc. - Brief Array BioPharma Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Array BioPharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Array BioPharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Array BioPharma Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Array BioPharma Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Array BioPharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Array BioPharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Array BioPharma Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Array BioPharma Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Array BioPharma Inc.; Array BioPharma Inc. - Key Therapeutics; Array BioPharma Inc. - Pipeline Overview and Promising Molecules; Array BioPharma Inc. - News; Array BioPharma Inc. - Latest Updates; Array BioPharma Inc. - Pipeline; Array BioPharma Inc. - Discontinued/Dormant Projects SHOW LESS READ MORE >

List of Tables
List of Figures
Array BioPharma Inc. Snapshot
Array BioPharma Inc. Overview
Key Information
Key Facts
Array BioPharma Inc. – Research and Development Overview
Key Therapeutic Areas
Array BioPharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Array BioPharma Inc. – Pipeline Products Glance
Array BioPharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Array BioPharma Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Array BioPharma Inc. – Drug Profiles
ARRY-162
Product Description
Mechanism of Action
R&D Progress
ARRY-334543 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
ARRY-334543 + Taxotere
Product Description
Mechanism of Action
R&D Progress
ARRY-380
Product Description
Mechanism of Action
R&D Progress
ARRY-382
Product Description
Mechanism of Action
R&D Progress
ARRY-520
Product Description
Mechanism of Action
R&D Progress
ARRY-520 + Bortezomib + Dexamethasone + G-CSF
Product Description
Mechanism of Action
R&D Progress
ARRY-520 + Bortezomib + G-CSF
Product Description
Mechanism of Action
R&D Progress
ARRY-520 + Velcade + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
ARRY-543
Product Description
Mechanism of Action
R&D Progress
ARRY-614
Product Description
Mechanism of Action
R&D Progress
ARRY-797
Product Description
Mechanism of Action
R&D Progress
ISIS 113715
Product Description
Mechanism of Action
R&D Progress
Varlitinib + Xeloda
Product Description
Mechanism of Action
R&D Progress
Array BioPharma Inc. – Pipeline Analysis
Array BioPharma Inc. – Pipeline Products by Therapeutic Class
Array BioPharma Inc. - Pipeline Products By Target
Array BioPharma Inc. – Pipeline Products by Route of Administration
Array BioPharma Inc. – Pipeline Products by Molecule Type
Array BioPharma Inc. – Recent Pipeline Updates
Array BioPharma Inc. - Dormant Projects
Array BioPharma Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ARRY-162
ARRY-797
Array BioPharma Inc. – Company Statement
Array BioPharma Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2006: Array BioPharma's p38 Inhibitor For Inflammatory Disease To Advance Into Human Clinical Trials
Nov 30, 2010: Array BioPharma Achieves Clinical Milestone In Celgene Collaboration
Nov 29, 2010: Array BioPharma To Present ARRY-520 Data At 2010 ASH Annual Meeting
Dec 28, 2006: Array BioPharma's KSP Inhibitor For Cancer To Advance Into Human Clinical Trials
Oct 26, 2008: Array BioPharma's Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit And Systemic Anti-Inflammatory Activity In A Phase II Trial
Apr 26, 2006: Array BioPharma Initiates Phase I Clinical Trial Of Its MEK Inhibitor For Inflammatory Disease
Mar 25, 2008: Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY-614, Into Phase 1 Clinical Trial
Oct 24, 2007: Array BioPharma Reports Positive New Data On ErbB-2 / EGFR Inhibitor, ARRY-543
Apr 21, 2009: Array BioPharma's ARRY-520 Demonstrates Significant Activity In Hematological And Taxane-Resistant Tumors
Apr 21, 2009: Array BioPharma's ARRY-543 Shows Potential Clinical Benefit In Cancer Patients
Nov 20, 2007: Array BioPharma Advances p38 Inhibitor, ARRY-797, Into Phase II Clinical Trial
Jun 20, 2007: Array BioPharma Reports New Clinical Data Of ARRY-797, Its Anti-Inflammatory Drugs
Jun 20, 2007: Array BioPharma Reports New Clinical Data On Its MEK inhibitor, ARRY-162
Oct 19, 2006: Array BioPharma Reports MEK Inhibitor, ARRY-438162, Meets Initial Clinical Objectives
Apr 19, 2009: Array BioPharma's ARRY-614 Demonstrates Cytokine Inhibition And Anti-Tumor Activity In Preclinical Models Of Hematological Cancers
Apr 18, 2005: Array BioPharma Presents Data On Cancer Program At The 96th Annual Meeting Of The American Association For Cancer Research
Jan 17, 2006: Array BioPharma Initiates Phase I Clinical Trial For Targeted Anticancer Drug ARRY-334543
Jul 15, 2009: Array Files IND Application for a Phase I Clinical Trial Of MEK Inhibitor in Cancer Patients
Jan 14, 2002: Array BioPharma Initiates A New Drug Discovery Program With Amgen
Dec 12, 2009: Array BioPharma Announces Interim Phase I Study Results Of ARRY-380 For The Trearment Of Advanced Cancer
Jun 12, 2008: Array BioPharma Presents Additional Positive Phase I Results At The 2008 Annual European Congress Of Rheumatology
Apr 10, 2007: Array BioPharma Advances p38 Inhibitor, ARRY-797, Into Phase I Cancer Patient Trial
Jan 09, 2009: Array BioPharma Initiates Phase 1 Clinical Trial For MEK Inhibitor ARRY-300
Aug 08, 2005: Array BioPharma's Anticancer Compound ARRY-334543 Cleared To Advance Into Human Clinical Trials
Jul 08, 2009: Array BioPharma Announces Top-Line Results In Two Phase I Clinical Trials
May 07, 2008: Array BioPharma Presents Additional Positive Phase II Results Of ARRY-797 In Inflammatory Pain Clinical Trial At The American Pain Society's Annual Scientific Meeting
Jun 05, 2010: Array Announces Positive Phase I Study Data For ARRY-520 In Multiple Myeloma Patients
Dec 04, 2010: Array BioPharma's Arry-520 Demonstrates Single Agent Activity In Advanced Multiple Myeloma
Sep 03, 2009: Array BioPharma Announces Top-Line Results From Rheumatoid Arthritis Phase II Trial
Aug 03, 2007: Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, Into Phase I Cancer Patient Trial
Mar 03, 2008: Array BioPharma Announces Positive Phase II Top-Line Results In Inflammatory Pain Clinical Trial
Mar 03, 2007: Array BioPharma Initiates Phase I Clinical Trial For Anticancer KSP Inhibitor ARRY-520
Oct 01, 2010: Array BioPharma Announces Positive Interim Phase I Results For ARRY-380 In Breast Cancer Patients
Financial Deals Landscape
Array BioPharma Inc., Deals Summary
Array BioPharma Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Array BioPharma Enters Into Co-Development Agreement With Genentech
Signal Genetics Enters Into An Agreement With Array BioPharma
Array BioPharma Enters Into An Agreement With Novartis
Array BioPharma Enters Into Agreement With Chemizon
Celgene Enters Into Agreement With Array BioPharma
Ono Pharmaceutical Enters Into Co-Development Agreement With Array BioPharma
Array BioPharma Expands Agreement With Genentech
Array BioPharma Expands Research Collaboration With Genentech
Array BioPharma Enters Into Co-Development Agreement With QLT
Array BioPharma Extends Co-Development Agreement With Trimeris
Array BioPharma Enters Into Co-Development Agreement With Takeda Chemical
Array BioPharma Enters Into Agreement With Genentech
Licensing Agreements
Array BioPharma Extends Licensing Agreement With InterMune
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharmaceuticals For ARRY-543
Array BioPharma Enters Into Licensing Agreement With Amgen
Array BioPharma Enters Into Licensing Agreement With VentiRx
InterMune Extends Its Agreement With Array BioPharma
CyDex Enters Into Licensing Agreement With Array BioPharma
Equity Offering
Array BioPharma Completes Private Placement Of $2 Million
Array BioPharma Completes Public Offering Of $91 Million
Array BioPharma Completes Public Offering Of $71 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Array BioPharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
Array BioPharma Inc. – Pipeline by Stage of Development, H2 2011
Array BioPharma Inc. - Phase II, H2 2011
Array BioPharma Inc. - Phase I, H2 2011
Array BioPharma Inc. - Pipeline By Therapeutic Class, H2 2011
Array BioPharma Inc. - Pipeline By Target, H2 2011
Array BioPharma Inc. – Pipeline By Route of Administration, H2 2011
Array BioPharma Inc. – Pipeline By Molecule Type, H2 2011
Array BioPharma Inc. – Recent Pipeline Updates, H2 2011
Array BioPharma Inc. - Dormant Developmental Projects, 2010
Array BioPharma Inc. - Discontinued Pipeline Products, 2010
Array BioPharma Inc., Other Locations
Array BioPharma Inc., Deals Summary
Array BioPharma Enters Into Co-Development Agreement With Genentech
Signal Genetics Enters Into An Agreement With Array BioPharma
Array BioPharma Enters Into An Agreement With Novartis
Array BioPharma Enters Into Agreement With Chemizon
Celgene Enters Into Agreement With Array BioPharma
Ono Pharmaceutical Enters Into Co-Development Agreement With Array BioPharma
Array BioPharma Expands Agreement With Genentech
Array BioPharma Expands Research Collaboration With Genentech
Array BioPharma Enters Into Co-Development Agreement With QLT
Array BioPharma Extends Co-Development Agreement With Trimeris
Array BioPharma Enters Into Co-Development Agreement With Takeda Chemical
Array BioPharma Enters Into Agreement With Genentech
Array BioPharma Extends Licensing Agreement With InterMune
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharmaceuticals For ARRY-543
Array BioPharma Enters Into Licensing Agreement With Amgen
Array BioPharma Enters Into Licensing Agreement With VentiRx
InterMune Extends Its Agreement With Array BioPharma
CyDex Enters Into Licensing Agreement With Array BioPharma
Array BioPharma Completes Private Placement Of $2 Million
Array BioPharma Completes Public Offering Of $91 Million
Array BioPharma Completes Public Offering Of $71 Million

List of Figures
Array BioPharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
Array BioPharma Inc. – Pipeline by Stage of Development, H2 2011
Array BioPharma Inc. – Pipeline By Therapeutic Class, H2 2011
Array BioPharma Inc. - Pipeline By Target, H2 2011
Array BioPharma Inc. – Pipeline By Route of Administration, H2 2011
Array BioPharma Inc. – Pipeline By Molecule Type, H2 2011